Les Groupes Coopérateurs en Oncologie à l`ASCO 2016

Lettre d’information du réseau GCO - Spéciale ASCO 2016
Les Groupes Coopérateurs en Oncologie à l’ASCO 2016
Les Groupes Coopérateurs en Oncologie (GCO) seront représentés au 52ème congrès de l’ASCO
(American Society of Clinical Oncology), qui se tiendra du 3 au 7 juin à Chicago (Etats-Unis).
L’ASCO est le principal rendez-vous de la cancérologie mondiale au cours duquel sont partagés les
résultats d’études cliniques sur le traitement des cancers. Comme chaque année, les GCO
présenteront leurs dernières études menées dans différentes pathologies cancéreuses
essentiellement les cancers gynécologiques, digestifs, bronchiques, les cancers de la tête et du cou,
les cancers du cerveau et du système nerveux central, les hémopathies malignes ainsi que les cancers
pédiatriques.
Nous vous invitons à découvrir dans cette lettre d’information les 10 communications orales et 25
posters qui portent sur des essais promus ou soutenus par l’un des neuf groupes membres des
GCO.
----------------------------------------------------------------------------------------------------------------CANCERS DE LA TETE ET DU COU
GORTEC : Groupe Oncologie Radiothérapie Tête et Cou
Abstract 6000 (communication orale)
Induction docetaxel platinum 5-FU (TPF) followed by cetuximab-radiotherapy (cetux-RT) versus
concurrent chemo-radiotherapy (CT/RT) in patients with N2b/c-N3 non operated stage III-IV
squamous cell cancer of the head and neck (SCCHN) : Results of the GORTEC 2007-02 phase III
randomized trial.
View abstract
Abstract 6003 (communication orale)
Cetuximab-radiotherapy versus cetuximab-radiotherapy plus concurrent chemotherapy in patients
with N0-N2a squamous cell carcinoma of the head and neck (SCCHN) : Results of the GORTEC 2007-01
phase III randomized trial.
View abstract
1
Lettre d’information des GCO - n°1 – Mai 2016
GCO/IFCT
10 rue de la Grange-Batelière - 75009 Paris
Tel: +33 1.80.96.08.03 http://www.gco-cancer.org/
CANCERS DIGESTIFS (COLORECTAUX ET NON COLORECTAUX)
FFCD : Fédération Francophone de Cancérologie Digestive
Abstract TPS4154 (poster)
GLOBAL BALLAD: An International Rare Cancers Initiative trial to evaluate the potential Benefit of
Adjuvant chemotherapy for smaLL bowel Adenocarcinoma (IRCI 002).
View abstract
Abstract 3531 (poster)
Final results of PRODIGE 9, a randomized phase III comparing no treatment to bevacizumab
maintenance during chemotherapy-free intervals in metastatic colorectal cancer.
View abstract
Abstract 3534 (poster)
Impact of genetic polymorphisms of VEGF pathway on the response to bevacizumab in metastatic
colorectal cancer (mCRC) : ancillary study of PRODIGE 9 trial.
View abstract
Abstract TPS4148 (poster)
REMINET: A european, multicentre, phase II/III randomized double-blind, placebo-controlled study
evaluating lanreotide as maintenance therapy after first-line treatment in patients with nonresectable duodeno-pancreatic neuroendocrine tumours.
View abstract
Abstract 3513 (poster)
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM):
Results of the FFCD 1102 phase II trial.
View abstract
Abstract 3532 (poster)
Obesity in metastatic colorectal cancer: Pooled analysis of FFCD trials.
View abstract
Abstract 3533 (poster)
Predictive validity of NeoAdjuvant Rectal (NAR) Score and pathologic complete response (ypCR) for
overall survival (OS) as surrogate endpoints in rectal cancer clinical trials.
View abstract
GERCOR : Groupe Coopérateur Multidisciplinaire en Oncologie
Abstract 3553 (poster)
Erlotinib added to bevacizumab as maintenance therapy and health-related quality of life in patients
with metastatic colorectal cancer: Results of the GERCOR DREAM phase III trial.
View abstract
Abstract 4120 (poster)
Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with
metastatic pancreatic adenocarcinoma: A GERCOR randomized phase II study (AFUGEM).
View abstract
2
Lettre d’information des GCO - n°1 – Mai 2016
GCO/IFCT
10 rue de la Grange-Batelière - 75009 Paris
Tel: +33 1.80.96.08.03 http://www.gco-cancer.org/
-------------------------------------------------------------------------------------------------------------------------------------CANCERS DU POUMON
IFCT : Intergroupe Francophone en Cancérologie Thoracique
Abstract 9005 (communication orale)
Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced
non-squamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103
ULTIMATE.
View abstract
Abstract 9076 (poster)
1001 CHIVA trial: A phase II study of carboplatin (Ca) plus pemetrexed (P) followed by P maintenance,
as first-line therapy for human immunodeficiency virus (HIV)–associated advanced non-squamous
non-small cell lung cancer (NS-NSCLC).
View abstract
Abstract 9077 (poster)
A phase II study assessing the benefit of cisplatin re-introduction (stop and go strategy) in patients
with advanced non-squamous non-small cell lung cancer (NSCLC): The IFCT-1102 BUCiL study (a
Better Use of Cisplatin in Lung cancer).
View abstract
Abstract 8568 (poster)
Pathological central review of 290 thymic epithelial tumors (TET): The national network
RYTHMIC experience.
View abstract
----------------------------------------------------------------------------------------------------------------CANCERS GYNECOLOGIQUES
ARCAGY - Association de Recherche sur les CAncers dont GYnécologiques
GINECO - Groupe d’Investigateurs Nationaux pour l’Étude des Cancers Ovariens et du sein
Abstract TPS5607 (poster)
PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as
maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based
chemotherapy plus bevacizumab.
View abstract
Abstract TPS5603 (poster)
NiCCC (ENGOT-GYN1): A randomized phase II study of nintedanib (BIBF1120) compared to
chemotherapy in patients with recurrent clear cell carcinoma of the ovary or endometrium.
View abstract
Abstract 5575 (poster)
Quality of life (QOL) to predict overall survival (OS) in women with platinum-resistant ovarian cancer
(PROC).
View abstract
3
Lettre d’information des GCO - n°1 – Mai 2016
GCO/IFCT
10 rue de la Grange-Batelière - 75009 Paris
Tel: +33 1.80.96.08.03 http://www.gco-cancer.org/
----------------------------------------------------------------------------------------------------------------CANCERS PEDIATRIQUES
SFCE : Société Française de lutte contre les Cancers et les leucémies de l’Enfant et de l’adolescent
Abstract 10507 (communication orale)
Results of the randomized intergroup trial Inter-B-NHL ritux 2010 for children and adolescents with
high risk B-cell non Hodgkin’s lymphoma and mature acute leukemia: Evaluation of rituximab efficacy
in addition to standard LMB chemotherapy regimen.
View abstract
Abstract 10514 (communication orale)
Two-year results of clinical efficacy of cisplatin in combination with sodium thiosulfate (STS) vs
cisplatin alone in a randomized phase III trial for standard risk hepatoblastoma (SR-HB): SIOPEL 6.
View abstract
Abstract 10555 (poster)
Dose-finding study of vinblastine in combination with nilotinib in children, adolescents and young
adults with refractory or recurrent low-grade glioma: Results of the ITCC/SIOPE-Brain VINILO phase I
trial (NCT01887522).
View abstract
Discussing abstracts 10515, 10516, 10517 (communication)
Advancing the Care of Children With Rare Malignancies Through Collaboration
View abstract
---------------------------------------------------------------------------------------------------------------HEMOPATHIES MALIGNES
LYSA : The LYmphoma Study Association
Abstract 7509 (communication orale)
Baseline total metabolic volume (TMTV) to predict the outcome of patients with advanced Hodgkin
lymphoma (HL) enrolled in the AHL2011 LYSA trial.
View abstract
Abstract 7518 (poster)
Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): An analysis of
twelve collaborative lymphoma study Association (LYSA) trials, the Simonal Study.
View abstract
Abstract 7547 (poster)
Classification of diffuse large b-cell lymphoma (DLBCL) FFPE samples of the GELA LNH2003 program,
using Lymph2Cx assay on the nCounter analysis system.
View abstract
4
Lettre d’information des GCO - n°1 – Mai 2016
GCO/IFCT
10 rue de la Grange-Batelière - 75009 Paris
Tel: +33 1.80.96.08.03 http://www.gco-cancer.org/
IFM : Intergroupe Francophone du Myélome
Abstract 8001 (communication orale)
Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell
transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS).
View abstract
---------------------------------------------------------------------------------------------------------------CANCERS DU CERVEAU ET DU SYSTEME NERVEUX CENTRAL
IGCNO : InterGroupe Coopérateur de Neuro-Oncologie
ANOCEF : Association des Neuro-oncologues d'Expression Française
Abstract LBA2 (communication orale)
A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and
adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG
08.02, NCT00482677).
View Abstract
Abstract LBA2000 (communication orale)
Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and
adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial.
Abstract
Abstract 2020 (poster)
Baseline plasma matrix metalloproteinase 9 (MMP9) to predict overall survival (OS) benefit from
bevacizumab (BEV) in newly diagnosed glioblastoma (GBM): Retrospective analysis of AVAglio.
Abstract
Abstract 2021 (poster)
Residual tumor volume and change in tumor volume during adjuvant therapy to predict long-term
survival in AVAglio: Phase 3 newly diagnosed glioblastoma patients treated with radiation,
temozolomide, and bevacizumab or placebo.
Abstract
Abstract 2033 (poster)
Phase I/II study of S49076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with
bevacizumab in patients with recurrent glioblastoma.
Abstract
Abstract 2048 (poster)
Radiologic progression types are treatment specific: An exploratory analysis of a phase 3 study of
bevacizumab plusradiotherapy plustemozolomide for patients with newly diagnosed glioblastoma
(AVAglio).
Abstract
5
Lettre d’information des GCO - n°1 – Mai 2016
GCO/IFCT
10 rue de la Grange-Batelière - 75009 Paris
Tel: +33 1.80.96.08.03 http://www.gco-cancer.org/
Abstract TPS2083 (poster)
MEVITEM: A European, randomized, open-label Phase I/II of vismodegib in combination with
temozolomide versus temozolomide alone in adult patients with recurrent/ refractory
medulloblastoma presenting an activation of the Sonic Hedgehog pathway.
Abstract
Abstract e14123 (poster)
Dose optimization of MK-8628 (OTX015), a small molecule inhibitor of bromodomain and extraterminal (BET) proteins, in patients (pts) with recurrent glioblastoma (GB).
Abstract
Abstract 2015 (poster)
Validation of the new glioma WHO classification in the French POLA Network: analysis of 1041 cases.
Abstract
-----------------------------------------------------------------------------------------------------------------
 Plus d’informations sur les GCO : http://www.gco-cancer.org/fr/
 Retrouvez tous les abstracts sur le site de l’ASCO : https://iplanner.asco.org/am2016/#/
6
Lettre d’information des GCO - n°1 – Mai 2016
GCO/IFCT
10 rue de la Grange-Batelière - 75009 Paris
Tel: +33 1.80.96.08.03 http://www.gco-cancer.org/